Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2021 10:00 ET | Source: Precipio, Inc.

New York State Approves Precipio’s HemeScreen for POL clinical use

NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...
August 26, 2021 10:00 ET | Source: Precipio, Inc.

American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory

NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...
January 20, 2021 10:00 ET | Source: Precipio, Inc.

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US,...
December 10, 2020 10:15 ET | Source: Precipio, Inc.

Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...
June 09, 2020 10:00 ET | Source: Precipio, Inc.

Precipio Adds Another HemeScreen™ Customer

NEW HAVEN, Conn., June 09, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted...
April 06, 2020 10:00 ET | Source: Precipio, Inc.

Precipio Launches New HemeScreen™ Reagent Rental Program

NEW HAVEN, Conn., April 06, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program....
September 30, 2019 11:10 ET | Source: Precipio, Inc.

First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™

NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...
April 03, 2019 07:38 ET | Source: Precipio, Inc.

Precipio’s HemeScreen™ Adopted by Methodist Health

NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected...
January 08, 2019 07:45 ET | Source: Precipio, Inc.

Precipio Files Patent for HemeScreen™, its Novel Molecular Assay

NEW HAVEN, Conn., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the filing of a patent for its proprietary HemeScreen panel....
October 03, 2018 07:47 ET | Source: Precipio, Inc.

Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers

Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...